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Purpose: Pseudocontinuous arterial spin labeling (pCASL) allows for noninvasive 
measurement of regional cerebral blood flow (CBF), which has the potential to serve 
as biomarker for neurodegenerative and cardiovascular diseases. This work aimed to 
implement and validate pCASL on the dedicated MRI system within the population-
based Rotterdam Study, which was installed in 2005 and for which software and 
hardware configurations have remained fixed.
Methods: Imaging was performed on two 1.5T MRI systems (General Electric);  
(I) the Rotterdam Study system, and (II) a hospital-based system with a product 
pCASL sequence. An in-house implementation of pCASL was created on scanner 
I. A flow phantom and three healthy volunteers (<27 years) were scanned on both 
systems for validation purposes. The data of the first 30 participants (86 ± 4 years) 
of the Rotterdam Study undergoing pCASL scans on scanner I only were analyzed 
with and without partial volume correction for gray matter.
Results: The validation study showed a difference in blood flow velocity, sensitivity, 
and spatial coefficient of variation of the perfusion-weighted signal between the two 
scanners, which was accounted for during post-processing. Gray matter CBF for the 
Rotterdam Study participants was 52.4 ± 8.2 ml/100 g/min, uncorrected for partial 
volume effects of gray matter. In this elderly cohort, partial volume correction for 
gray matter had a variable effect on measured CBF in a range of cortical and sub-
cortical regions of interest.
Conclusion: Regional CBF measurements are now included to investigate novel bio-
markers in the Rotterdam Study. This work highlights that when it is not feasible to 
purchase a novel ASL sequence, an in-house implementation is valuable.
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1 |  INTRODUCTION
Measurement of regional cerebral blood flow (CBF) with 
pseudocontinuous arterial spin labeling (pCASL) is a cost- 
effective and safe option for repeated assessment of regional 
cerebral perfusion without the need to administer contrast 
media. This technique allows for quantification of CBF in 
ml/100 g/min and is, therefore, especially attractive for large 
and longitudinal population-based studies in which healthy 
participants undergo MRI scans at multiple time points along 
the course of the study period.
The Rotterdam Study1 is a prospective population-based 
cohort study ongoing since 1990 in the city of Rotterdam 
in The Netherlands, which targets cardiovascular, endocrine, 
hepatic, neurological, ophthalmic, psychiatric, dermatolog-
ical, otolaryngological, locomotor, and respiratory diseases. 
The Rotterdam Scan Study2 is a substudy and focuses spe-
cifically on (repeat) brain MRI examinations to study neuro-
degenerative and cerebrovascular disease and was officially 
embedded in the core protocol of the Rotterdam Study in 
2005, when a dedicated MRI system was installed in the 
Rotterdam Study Research Centre. To maintain consistency 
in image acquisition, the MRI hardware and software have 
not changed since.
Evidence for regional CBF as a biomarker in healthy 
aging,3,4 cardiovascular disease,5 and neurodegeneration6 is 
steadily building in the literature. However, the original MRI 
protocol of the Rotterdam Scan Study only contained a phase 
contrast assessment of blood flow through major brain feed-
ing arteries, assessing total CBF. The reason for this is that, 
despite ASL first being introduced in the early 1990s, the 
adoption of ASL as one of the standard sequences available 
on MRI systems is only a recent development due to the 2015 
consensus paper.7
Here we present the process of implementing and validat-
ing pCASL on the MRI system within the Rotterdam Study 
Research Centre. The validation of this pCASL sequence was 
done by CBF measurements of a novel perfusion phantom 
and healthy volunteers and comparing these to CBF measure-
ments with a novel product pCASL sequence on one of the 
1.5T MRI systems at the main site of the Erasmus Medical 
Centre in Rotterdam. In addition, the first 30 ASL datasets 
were assessed for their ability to measure regional CBF, cor-
rected for partial volume estimates of gray matter, in the el-
dest cohort of participants of the Rotterdam Study.
We present this work to illustrate how local, multidisci-
plinary collaborations between MR physicists, engineers, 
and radiologists can result in successful implementation of a 
novel imaging technique. The need for ASL in the Rotterdam 
Study was given by a radiologist and epidemiologist and 
the process of programming and compiling the ASL se-
quence was done by physicists. During the optimization of 
the image analysis pipeline, the role of the engineer was to 
show that  the sequence was working as intended (introduc-
tion of the phantom experiment) and communicate between 
the physics and radiologists teams in optimizing the process-
ing pipeline. The final implementation was done via close 
collaboration between the MR Physics and Population-Based 
Imaging groups at the department of Radiology and Nuclear 
Medicine of the Erasmus MC. This work shows that porting a 
novel MRI sequence to an older MRI system is valuable and, 
therefore, may be beneficial for sites that do not have the op-
tion to purchase novel ASL sequences for their MRI systems 
and software versions.
2 |  METHODS
All imaging was performed on 1.5T MRI systems (General 
Electric Healthcare, Milwaukee, WI, USA). Experiments 
were conducted under approval of the institutional ethics 
committee, in compliance with the declaration of Helsinki.
2.1 | Implementation and validation of ASL 
in population based imaging
Imaging was performed on two different 1.5T MRI sys-
tems; (a) the population imaging scanner, a Signa EXCITE 
with software version 11 (released November 2003) and an 
8-channel head coil; (b) an Optima MR450w 1.5T with soft-
ware version DV26 (released June 2017) and a 24-channel 
head coil, which includes the General Electric product ver-
sion of pCASL.8 The implementation of pCASL at scan-
ner I was done in-house, converting the product pCASL 
sequence from software version DV26 to 11. This was 
done by mimicking the product sequence as much as pos-
sible hereby keeping up with the theoretical background of 
the implementation of the product sequence.9,10 This was a 
debugging process that required downgrading novel func-
tions and input structures from DV26, ensuring that the 
sequence could be compiled for software version 11. This 
particular part of porting back the sequence is highly 
 dependent on both software versions and required close col-
laboration with GE. The final step in coding the in-house 
pulse sequence was to fine-tune the unbalancing of the ra-
diofrequency (RF) gradients used to generate the label and 
control images. This process ensures that the effects of phase 
shifts between RF pulses in the pseudocontinuous labeling 
caused by magnetic field inhomogeneities at the labeling 
plane are minimalized, ensuring that the labeling efficiency 
of the pCASL scan was as high as possible.10,11 Please note 
that we cannot publish any code of the pulse sequence, since 
this is GE proprietary information. However, via the GE 
research collaboration portal, we are open to collaborations 
in which this experience is shared.
   | 3WARNERT ET Al.
Acquisition parameters were the same for both pCASL 
implementations; 3D spiral gradient echo read-out with 
background suppression, 512 points per arm, eight arms, 
reconstruction diameter = 200  mm, reconstruction ma-
trix 128 × 128 × 30, slice thickness 4 mm, post label delay 
(PLD) 1.525 s, label duration 1.45 s, number of excitations = 
3, echo time = 0.011 s, repetition time = 4.6 s. Each pCASL 
acquisition included a proton density weighted image for nor-
malization (the same acquisition parameters, but no labeling 
applied9).
2.2 | Phantom experiment
A perfusion phantom (beta test version of QASPER, Gold 
Standard Phantoms, London, UK), which allows for setting 
variable continuous flow rates, was used. Measurements 
were done on both MRIs systems at two different days, 
2 weeks apart. Per session, 12 pCASL scans were made in ran-
dom order for different flow rates (200-475 ml/min, steps of 
25 ml/min). Voxelwise perfusion-weighted images (ΔM/M0) 
were calculated for each pCASL scan.9 Median values were 
calculated over a circular region of interest (ROI), which was 
placed over the perfusion region of the phantom via visual 
inspection. A scaling factor between the two sequences was 
calculated by dividing the ROI median ΔM/M0,DV26 by the 
ROI median ΔM/M0,11.
2.3 | Healthy, young volunteer experiment
Three  young healthy volunteers (all female, <27 years) 
 underwent pCASL scanning on both MR systems on the 
same day. Perfusion-weighted pCASL images before quan-
tification were compared by calculating the signal-to-noise 
ratio (SNR) of ΔM as the mean perfusion-weighted signal 
in the GM divided by the standard deviation of a circular 
ROI (radius of 10 voxels) well outside the brain12 and by 
calculating the spatial coefficient of variation (CoV) within 
the whole brain GM ROI.13 The whole brain GM mask was 
obtained via segmentation of a T1 – weighted structural scan 
(fast in FSL), which was linearly registered to the pCASL 
image (flirt in FSL) and only included voxels with partial 
volume estimates for GM (PVEGM) > 70%. CBF maps were 
quantified with oxford_asl (FSL, version 6.0.1, Oxford, 
UK),7 taking into account the scaling factor between the two 
implementations resulting from the phantom experiment. In 
addition, 16 cortical and sub-cortical ROIs from the Harvard-
Oxford atlas (thresholded at partial volume estimates > 25%) 
were nonlinearly transformed from MNI standard space to 
the participant’s pCASL space and used to calculate the ab-
solute differences in ROI CBF calculated between scanner I 
and scanner II.
2.4 | Application of ASL imaging in the 
Rotterdam scan study
Thirty elderly participants (20 females, mean age 86 ± 4 
years) of the RS-I cohort in the Rotterdam Study (study entry 
in 1989-1993) underwent scanning on scanner I only (Sep-
Nov 2018). SNR, CoV, and ROI average CBF were calcu-
lated in the same manner as for the young volunteers. To 
show the potential and advantage of being able to investigate 
regional CBF, a comparison was made of CBF calculated 
with and without PVE correction to assess the effect of local 
GM volume (BASIL within FSL14).
3 |  RESULTS
3.1 | Implementation and validation of 
pCASL
The flow phantom results illustrate a difference in flow sen-
sitivity of ΔM/M0 between the two pCASL implementations, 
with the pCASL on scanner I being more sensitive to increas-
ing flow velocities (Figure 1). The scaling factor between the 
two pCASL implementations has an exponential relation-
ship, with an asymptote at 30.9 (Figure 1B).
For the healthy, young volunteers the SNR of the perfusion- 
weighted signal directly resulting from image reconstruction 
was smaller and CoV was larger for scanner I than for scan-
ner II (Table 1 and Figure 2). When taking the scaling fac-
tor and additional smoothing into account, group averaged 
CBFGM (uncorrected for PVE of GM) for scanner I and II in 
the healthy volunteers were similar: 63.3 ± 1.8 ml/100 g/min 
and 62.2 ± 2.0 ml/100 g/min, respectively. Figure 3 shows the 
differences in CBF between the two scanners for the whole 
brain GM and 16 cortical and sub-cortical ROIs calculated 
for all three volunteers. Note that, except for the brainstem, 
ROI differences in CBF for the two scanners are on the order 
of ±6 ml/100 g/min.
3.2 | Application of ASL imaging in the 
Rotterdam scan study
The dataset of one elderly participant was excluded due to 
 severe head motion during the pCASL acquisition. Group 
averaged SNR of the perfusion-weighted signal was lower 
for the elderly participants than for the younger, while spatial 
CoV of the perfusion-weighted signal for the whole brain GM 
was higher than for the young volunteers. Both values are 
reported in Table 1. Group averaged whole brain GM CBF 
for the 29 remaining elderly participants was increased when 
correcting for PVEGM: 52.4 ± 8.2 ml/100 g/min vs 63.0 ± 
8.9 ml/100  g/min, uncorrected and corrected for PVEGM, 
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respectively (paired t test, P < .001). Regional investigation 
showed that the increase in GM CBF with partial volume cor-
rection varies across the brain, ranging from no significant 
change in CBF in brainstem (paired t test, P = 0.353) and 
cerebellum (paired t test, P = 0.345) to a little over 50% in the 
caudate nucleus (Figure 4).
4 |  DISCUSSION
This work shows the in-house implementation and valida-
tion of pCASL on a population imaging MRI system, with 
an outdated software platform. The first 30 pCASL datasets 
acquired in the Rotterdam Study highlight the potential of 
using pCASL for monitoring regional cerebral perfusion in 
population imaging, even on older software platforms.
The flow phantom scans led to the inclusion of a scaling 
factor in the quantification of CBF in the pCASL scans of 
the population-based scanner. The results of the phantom ex-
periment indicate that labeling efficiency decreases at lower 
blood flow velocities (<30 cm/s) in our in-house implementa-
tion of pCASL. This is likely due to the difference in gradient 
coils between the two scanners. The asymptote of the scaling 
factor between the two different implementations (Figure 1B) 
suggests that, in the healthy population, a constant scaling 
factor is sufficient to correct for this difference in labeling 
efficiency. However, care should be taken in participants 
of the Rotterdam Study with blood flow velocities through 
the major cerebral arteries (<30 cm/s) in the labeling plane 
of the pCASL sequence. Within the Rotterdam Scan Study 
protocol phase contrast measurements of the flow velocities 
through the internal carotid and basilar arteries are measured. 
Therefore, the non-constant scaling factor as measured with 
the flow phantom is being incorporated in the CBF analysis 
of the complete cohort.
The use of a flow phantom is highly recommended when 
comparing pCASL implementations, because it allows for an 
objective manner to test the reproducibility of the CBF mea-
surements between two different scanners. However, should 
a flow phantom not be available, it is important to note that, 
in healthy volunteers, cerebral perfusion is variable due to 
several physiological parameters, including blood caffeine 
levels, blood pressure, hormone levels, etc. In absence of a 
flow phantom, it is important to compare sequences/scanners 
in light of previously reported reproducibility of ASL-based 
measurements of CBF.15
There are different reconstruction engines implemented in 
the software versions of scanner I and scanner II, which results 
in different inherent scaling of the perfusion-weighted signal 
compared with the M0 image as well as different smoothing of 
images directly resulting from the reconstruction. The recon-
struction engine as implemented in scanner II (DV26), does 
not allow for the reconstruction of the raw ΔM images and 
therefore it was not feasible to investigate ΔM images with-
out smoothing for scanner II. The differences in smoothing 
between the scanners leads to the higher spatial CoV in the 
perfusion-weighted images of scanner I, clearly seen in the 
healthy volunteers (Figure 2), which is the reason for includ-
ing additional spatial smoothing in the post processing of these 
F I G U R E  1  A, ΔM/M0 plotted against the flow velocity set for the flow phantom for the pCASL implementation at software version 11 (solid 
line, left y-axis) and for the implementation at DV26 (dashed line, right y-axis). B, Scaling factor (SF) between ΔM/M0 within perfusion ROI of 
the phantom collected with pCASL sequences at DV26 and at 11. SF is dependent on the flow velocity of the perfusate at the location of labeling, 
with a fitted asymptote of 30.9 (close to GE’s scaling factor of 32, used in image recon at DV26). The gray box indicates the range of mean flow 
velocities in the internal carotid and vertebral arteries in a healthy population (N = 180, 20-79 years), measured with Doppler sonography17
T A B L E  1  SNR for perfusion-weighted (ΔM) signal within the 
whole brain GM ROI (thresholded at PVEGM > 70%)
Participants SNR ΔMGM CoV ΔMGM
Young (N = 3)    
Scanner I 8.9 ± 0.4 30.3 ± 0.3 %
Scanner II 18.6 ± 1.4 25.1 ± 0.9 %
Elderly (N = 29)    
Scanner I 5.9 ± 1.1 36.9 ± 2.2%
   | 5WARNERT ET Al.
F I G U R E  2  Example of perfusion 
weighted (ΔM) images of one young 
volunteer. Note the difference in smoothing 
occurring during the reconstruction of the 
images. On scanner I with software version 
11 (top row), no smoothing is implemented 
during reconstruction. On scanner II with 
software version DV26 (bottom row), 
smoothing occurs during reconstruction of 
the images
F I G U R E  3  Absolute differences in regional CBF estimates between scanner I and scanner II in healthy volunteers. Note that these 
differences are calculated in ml/100 g/min. The dotted line is there as a reference at 0, that is, represents no difference in ROI average CBF between 
scanner I and scanner II. GM = gray matter, BS = brainstem, FL = frontal lobe, OL = occipital lobe, TL = temporal lobe, PL = parietal lobe,  
Ce = cerebellum, Ins = insular cortex, ACC = anterior cingulate cortex, PCC = posterior cingulate cortex, Tha = thalamus, Cau = caudate nucleus, 
Put = putamen, Pal = pallidum, Hip = hippocampus, Am = amygdala, Ac = Accumbens
F I G U R E  4  Top: Group averaged (N = 29) regional CBF values for elderly participants of the Rotterdam Scan Study, uncorrected and 
corrected for partial volume estimates of gray matter (GM). The error bars indicate the standard deviation across the group. The dotted line 
indicates the group averaged, uncorrected value for whole brain grey matter CBF. Bottom: The percentage in CBF per ROI after partial volume 
correction. GM = gray matter, BS = brainstem, FL = frontal lobe, OL = occipital lobe, TL = temporal lobe, PL = parietal lobe, Ce = cerebellum, 
Ins = insular cortex, ACC = anterior cingulate cortex, PCC = posterior cingulate cortex, Tha = thalamus, Cau = caudate nucleus, Put = putamen, 
Pal = pallidum, Hip = hippocampus, Am = amygdala, Ac = Accumbens. *Significantly larger than 0, P < .001. (Bonferroni-corrected  
P-value = .0029)
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images. The higher SNR for the perfusion-weighted signal on 
scanner II is likely caused by both the scaling and smoothing 
differences during reconstruction. However, note that the SNR 
for ΔM for young volunteers at scanner I is already in line with 
the results for 3D acquisitions as reported by Vidorreta et al12 
(and using the latest reconstruction engine clearly improves 
this value). Rather than changing these aspects of the recon-
struction engines, which can lead to revoking CE/FDA mark-
ing of the system, we opted for adapting the post-processing 
pipeline of the pCASL data for scanner I.
Limited differences were found between regional CBF 
measured with pCASL on scanner I and scanner II when tak-
ing the smoothing and scaling differences between the two 
software versions into account in the processing pipeline of 
perfusion-weighted images from scanner I. The variability of 
CBF measured with ASL at different scanners is known to 
fluctuate in the order of >17%, as reported previously.15 We 
therefore deemed the ±6 ml/100 g/min (<10% of the whole 
brain GM average) an acceptable range of fluctuation for the 
validation of this exam. The exception to this is the region of 
the brainstem, with a lower average CBF in scanner I. From 
previous work it is known that ASL requires optimisation for 
accurate brainstem CBF measurement.16 Our validation study 
highlights this aspect and indicates that it may not be feasi-
ble to make inferences about CBF in the brainstem within 
the Rotterdam Scan study. Note that extending the number of 
young healthy volunteers could have aided a more thorough 
comparison in regional CBF measurements between scanner I 
and scanner II. However, the combination of the phantom and 
young volunteer results gave us confidence that the pCASL 
implementation on scanner I was functioning appropriately 
and application in the Rotterdam Scan Study followed.
The added value of measuring regional CBF within the 
Rotterdam Scan Study is illustrated by the first datasets of 
the elderly cohort. The regional PVEGM correction for CBF 
(Figure 4) illustrates the capability of assessing the effect 
of local GM volume on CBF measurement and highlights 
that the underestimation of underlying GM CBF due to par-
tial volume effects is dependent on the ROI. The latter can 
be explained by the aspect that for subcortical gray mat-
ter structures (such as the caudate nucleus) the voxel size 
within the ASL sequence allows for limited voxels solely 
consisting of GM. The possibility of taking these regional 
variations in GM volume into account for the CBF mea-
surements will allow for disentangling the effect of changes 
in measured CBF due to a true change in GM perfusion or 
to GM atrophy.14 Note that this is valuable information in 
the context of the longitudinal Rotterdam Study and the in-
corporation of the current ASL processing pipeline within 
the analysis of the complete dataset of this cohort is now 
in progress. Future work with this data set, therefore, in-
cludes investigating the effect of aging and GM atrophy on 
regional CBF measurements.
A limitation of this work is the PLD of 1525 ms, which 
we chose based on the T1 of blood at 1.5T (1350  ms), 
the knowledge that the majority of the participants being 
scanned in the Rotterdam Scan Study are healthy, and to 
keep the imaging protocol consistent across all cohorts. 
Although this PLD led to SNR and CoV values compara-
ble with the literature for the young volunteers, the lower 
SNR and higher CoV for the elderly participants may be 
improved with a longer PLD, for example, 2000 ms as rec-
ommended by the ASL White Paper.7 This is based on the 
assumptions that the longer PLD will lead to less macro-
vascular artifacts within the perfusion-weighted images, 
because it would accommodate the expected longer arterial 
arrival times occurring in healthy aging7 and that this af-
fects the SNR and CoV in a stronger positive manner than 
the decrease in signal of the labeled blood because of T1 
relaxation during the prolonged PLD. In summary, this 
work illustrates the successful application of an in-house 
implementation of pCASL in the Rotterdam Scan Study, in-
cluding validation of this sequence with a novel flow phan-
tom. The regional CBF data that are now acquired within 
the study population will be used in the future to investigate 
novel biomarkers of neurodegenerative and cardiovascular 
disease in the Rotterdam Study.
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